Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CESAR RODRIGUEZ VALDES

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1518178805
CMS profile
250816
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$49,064.97

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CESAR RODRIGUEZ VALDES

NPI 1518178805 · CMS profile ID 250816

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518178805?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CESAR RODRIGUEZ VALDES, NPI 1518178805, CMS profile ID 250816. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518178805?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CESAR RODRIGUEZ VALDES, NPI 1518178805, CMS profile ID 250816. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518178805?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CESAR RODRIGUEZ VALDES, NPI 1518178805, CMS profile ID 250816, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518178805?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $49,064.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Legend Biotech USA Inc. $1,460.0002/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131692098 CMS
Janssen Biotech, Inc. $5,995.0002/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078843817 CMS
Janssen Scientific Affairs, LLC $27.3401/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078855706 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,255.0001/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144966061 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49,248.97 42
PY2020 $6,529.66 5
PY2021 $11,534.16 13
PY2022 $60,324.80 57
PY2023 $87,379.64 70
PY2024 $49,064.97 54
PY2025 $48,796.84 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $736,031.13 46
PY2024 Principal investigator $350,322.30 24
PY2023 Recipient $50.00 1
PY2023 Principal investigator $259,133.35 6
PY2022 Principal investigator $53,037.60 5
PY2021 Principal investigator $193,207.12 18
PY2020 Principal investigator $471,937.90 48
PY2019 Principal investigator $1,129,652.82 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,484.67 12/11/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202530306
Principal investigator 1 ABBVIE INC. $50,110.65 12/04/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202528606
Principal investigator 1 ABBVIE INC. $3,456.00 12/04/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202528608
Principal investigator 1 ABBVIE INC. $425.00 11/19/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524636
Principal investigator 1 ABBVIE INC. $2,400.00 11/19/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524734
Principal investigator 1 ABBVIE INC. $4,969.35 11/13/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524313
Principal investigator 1 ABBVIE INC. $6,594.75 11/06/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202523307
Principal investigator 1 ABBVIE INC. $5,975.10 11/04/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202520465
Principal investigator 1 ABBVIE INC. $68,332.95 11/04/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202520467
Principal investigator 1 ABBVIE INC. $100.00 10/09/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202515271
Principal investigator 1 ABBVIE INC. $94,591.80 10/09/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202515273
Principal investigator 1 ABBVIE INC. $3,456.00 10/09/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202515495
Principal investigator 1 ABBVIE INC. $4,969.35 10/08/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202513575
Principal investigator 1 ABBVIE INC. $3,901.36 09/10/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202510556
Principal investigator 1 ABBVIE INC. $6,912.00 09/03/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202507555
Principal investigator 1 ABBVIE INC. $145,080.45 09/03/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202507561
Principal investigator 1 ABBVIE INC. $1,500.00 09/03/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202508414
Principal investigator 1 ABBVIE INC. $1,500.00 09/03/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202508416
Principal investigator 1 ABBVIE INC. $2,484.67 08/08/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202504173
Principal investigator 1 ABBVIE INC. $72,941.85 08/05/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202501078
Principal investigator 1 ABBVIE INC. $6,010.00 08/05/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202501080
Principal investigator 1 ABBVIE INC. $3,456.00 08/05/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202501082
Principal investigator 1 ABBVIE INC. $12,720.00 07/24/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202499470
Principal investigator 1 Amgen Inc. $2,181.27 07/23/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma No dispute reported 06/30/2026 1246651826
Principal investigator 1 ABBVIE INC. $84,262.95 07/02/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202493943
Principal investigator 1 ABBVIE INC. $3,456.00 07/02/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202493945
Principal investigator 1 ABBVIE INC. $6,037.50 07/02/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202496739
Principal investigator 1 ABBVIE INC. $100.00 06/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202491039
Principal investigator 1 ABBVIE INC. $750.00 06/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202491041
Principal investigator 1 ABBVIE INC. $100.00 06/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202491043
Principal investigator 1 ABBVIE INC. $10,368.00 06/03/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202487485
Principal investigator 1 ABBVIE INC. $15,287.50 05/27/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202486249
Principal investigator 1 ABBVIE INC. $425.00 05/15/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202485097
Principal investigator 1 ABBVIE INC. $100.00 05/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202484633
Principal investigator 1 ABBVIE INC. $750.00 05/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202484637
Principal investigator 1 ABBVIE INC. $100.00 05/12/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202484639
Principal investigator 1 ABBVIE INC. $16,521.30 05/07/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202483639
Principal investigator 1 ABBVIE INC. $4,814.10 05/06/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202481965
Principal investigator 1 ABBVIE INC. $11,910.00 04/24/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202478993
Principal investigator 1 ABBVIE INC. $4,814.10 04/03/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202470066
Principal investigator 1 ABBVIE INC. $44,207.10 04/03/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202470285
Principal investigator 1 ABBVIE INC. $4,814.10 03/06/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
M22-947 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202456530
Principal investigator 1 ABBVIE INC. $6,745.68 02/19/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202452618
Principal investigator 1 ABBVIE INC. $2,407.05 02/05/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
M22-947 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202445793
Principal investigator 1 ABBVIE INC. $6,693.43 01/27/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202441443
Principal investigator 1 ABBVIE INC. $4,814.10 01/02/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF
M22-947 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1202435759